The Movember Foundation&apos;s GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date by S.M. Bruinsma et al.
The Movember Foundation’s GAP3 cohort: a proﬁle
of the largest global prostate cancer active
surveillance database to date
Sophie M. Bruinsma* , Liying Zhang†, Monique J. Roobol*, Chris H. Bangma*, Ewout
W. Steyerberg‡, Daan Nieboer*‡ and Mieke Van Hemelrijck§ Movember Foundation’s
Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortiuma
*Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands, †Sunnybrook Health
Sciences Centre, University of Toronto, Toronto, ON, Canada, ‡Department of Public Health, Erasmus University Medical
Centre, Rotterdam, The Netherlands, and §Division of Cancer Studies, Translational Oncology and Urology Research,
King’s College London, London, UK
aThe Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium members presented in
Appendix A.
Objectives
The Movember Foundation launched the Global Action Plan
Prostate Cancer Active Surveillance (GAP3) initiative to
create a global consensus on the selection and monitoring of
men with low-risk prostate cancer (PCa) on active
surveillance (AS). The aim of this study is to present data on
inclusion and follow-up for AS in this unique global AS
database.
Patients and Methods
Between 2014 and 2016, the database was created by
combining patient data from 25 established AS cohorts
worldwide (USA, Canada, Australasia, UK and Europe). Data
on a total of 15 101 patients were included. Descriptive
statistics were used to report patients’ clinical and
demographic characteristics at the time of PCa diagnosis,
clinical follow-up, discontinuation of AS and subsequent
treatment. Cumulative incidence curves were used to report
discontinuation rates over time.
Results
At diagnosis, the median (interquartile range [IQR]) patient
age was 65 (60–70) years and the median prostate-speciﬁc
antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had
clinical stage T1 disease (71.8%), a biopsy Gleason score of
6 (88.8%) and one tumour-positive biopsy core (60.3%).
Patients on AS had a median follow-up time of 2.2 (1.0–
5.0) years. After 5, 10 and 15 years of follow-up,
respectively, 58%, 39% and 23% of patients were still on
AS. The current version of GAP3 has limited data on
magnetic resonance imaging (MRI), quality of life and
genomic testing.
Conclusions
GAP3 is the largest worldwide collaboration integrating
patient data from men with PCa on AS. The results will allow
individual patients and clinicians to have greater conﬁdence
in the personalized decision to either delay or proceed with
active treatment. Longer follow-up and the evaluation of
MRI, new genomic markers and patient-related outcomes will
result in even more valuable data and eventually in better
patient outcomes.
Keywords
adenocarcinoma, guideline, evidence-based, #PCSM,
#ProstateCancer
Introduction
Prostate cancer (PCa) is the second most common cancer in
men, with nearly a million new cases diagnosed worldwide in
2008[1]. The number of men living with a diagnosis of PCa
is likely to continue to increase as the population in many
countries continues to age and as cancer is detected earlier,
owing to the more widespread use of serum PSA testing [2,3].
As a result, active surveillance (AS) was introduced as a
management strategy for men with low-risk PCa, with the
intention to start curative treatment at the time of
progression, and to avoid overtreatment and its associated
morbidities. In recent years, AS has evolved from an
experimental protocol to a broadly accepted management
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strategy for men diagnosed with low-risk PCa [4].
Contemporary data suggest that use of AS has increased
globally [5–7].
Nevertheless, identiﬁcation of those men whose disease is at
low risk for progression is a critical and much debated issue
when deciding which men will beneﬁt from AS for their PCa
[8]. Numerous agencies have endorsed clinical practice
guidelines for the management of low-risk PCa, which
include criteria for enrolment of patients in AS programmes
and their subsequent management [3]; however, there is
currently no consensus in this area. There has been shown to
be variability in enrolment criteria and follow-up in
international and national series of AS [9]. Moreover, robust
data from men with clinically insigniﬁcant PCa who are
undergoing AS, especially from studies with long follow-up
durations, are still limited. Hence, many important questions
regarding AS remain unanswered, such as which newly
diagnosed men should be considered suitable candidates for
AS and what constitutes an appropriate follow-up regimen
for AS [10]. There is a need for a worldwide consensus
regarding the optimal criteria and protocols for AS and more
comparative data on patient selection and testing protocols
[11].
In August 2014, the Movember Foundation launched the
Global Action Plan Prostate Cancer Active Surveillance
initiative (GAP3). Milestones of the project include a global
AS database for clinical, marker-related and imaging data. Its
primary goal is to create a global consensus on the selection
and monitoring of men with low risk PCa. Ultimately,
worldwide uniform guidelines will be developed. The aim of
the present study was to present data from this unique global
dataset on inclusion and follow-up for AS in men with low-
risk PCa.
Patients and Methods
Study Population
Between 2014 and 2016, a global database was created by
combining patient data from established AS cohorts
worldwide. To assemble existing cohorts into a large
consortium of cohorts, a new collaborative framework was
needed. The GAP3 partners therefore developed
documentation required for sharing and use of clinical data
within the global database. The database has been developed
at the site of Philips Electronics Nederland B.V., Eindhoven,
the Netherlands and is currently hosted by the Erasmus
Medical Centre, Rotterdam, the Netherlands [12]. The GAP3
initiative was initiated and is coordinated by the Erasmus
Medical Centre, Rotterdam, the Netherlands. The Movember
Foundation is the sole funder of the project.
Funding has now been secured to provide sustainability of
the GAP3 database until February 2019.
Requirements for participation in GAP3 included, among
others, ethical approval for sharing digital patient data in a
centralized global database, and an active registry of AS
patients over the last 2 years or more, including at least ~50
patients annually. To date, 25 centres from the USA, Canada,
Australasia, the UK and Europe fulﬁlled the requirements for
participation and joined the initiative (Table S1). References
to the individual AS cohorts can be found in Table S1. The
global database currently comprises data on 15 101 patients
(Table S1; database version ‘gap3data_2.3’, released in June
2017). A summary of the entry criteria for each individual AS
cohort is included in Table S2.
Although many variations in protocols currently exist, most
agree that the most suitable patients for AS are those aged
>18 years, and those with pretreatment clinical stage T1–T2
PCa, serum PSA ≤10 ng/mL, a biopsy Gleason score of ≤6 or
(3+4) 7, and a maximum of two tumour-positive biopsy core
samples. Some protocols included PSA density (most often
using a threshold of 0.2 ng/mL2), the maximum extent of
cancer per core (most often using a threshold of 50%) and
life expectancy (>10 years) and adequate biopsy sampling as
inclusion criteria for AS. As a result the following baseline
host (e.g. age, body mass index, race, ethnicity, marital status,
educational level, family history of PCa, smoking history and
comorbidities/overall health status) and tumour characteristics
(e.g. clinical stage, PSA, prostatic volume, biopsy Gleason
score, PSA density, number of biopsy cores with PCa, and
maximum cancer extent per core) were recorded.
In addition to baseline information, follow-up information
was key for the entire GAP3 project; it will allow us to
shed light on current practice and outcomes, with the ﬁnal
goal of providing consensus guidelines. A summary of the
monitoring strategy for each individual AS cohort is
included in Table S3. After initiation of AS, almost all
protocols recommend serial measurement of serum PSA
levels, DRE and surveillance biopsy sampling in order to
identify pathological progression. Many uncertainties remain
surrounding the optimum timing of these surveillance
strategies. Some protocols recommend PSA measurements
every 3 months, while others state that serum PSA
monitoring should be implemented at intervals no more
often than every 6 months after the start of AS. Some
protocols recommend DRE every 6 months, whilst others
do not include DRE in follow-up as a result of the use of
MRI. Substantial variation exists in the recommended
frequency at which rebiopsy procedures should be
conducted. Further, several protocols consider MRI for
routine use in AS, again with differences between the
recommended frequency, although most protocols
recommend a 12-month interval. PSA kinetics and quality-
of-life data are less frequently recommended as methods to
identify whether or not a patient’s cancer has progressed.
We therefore collected follow-up information on, for
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example, PSA, PSA kinetics (PSA doubling time and PSA
velocity), T stage by DRE, biopsy characteristics and
MRI ﬁndings (e.g. suspicious lesions found on MRI).
Finally, the database contains information on
discontinuation of AS (e.g. the reasons for stopping AS),
potential subsequent treatments (e.g. radical prostatectomy),
and cause of death.
Statistical Analyses
Descriptive statistics were used to assess the clinical and
demographic characteristics at time of PCa diagnosis for all
men included in the GAP3 cohort, their clinical follow-up,
discontinuation of AS and potential subsequent treatments.
Cumulative incidence curves were used to report
discontinuation rates over time [13]. R software was used to
perform all analyses [14].
Results
The GAP3 database currently comprises data on 15 101
patients from 25 centres across 15 countries (database
version ‘gap3data_2.3’, released in June 2017). At time of
diagnosis, the median (interquartile range [IQR]) patient
age was 65 (60–70) years, the median (IQR) PSA was 5.4
(4.0–7.3) ng/mL, the median (IQR) PSA density was 0.12
(0.09–0.17) ng/mL and the median (IQR) prostate volume
was 43.2 (33–59) cc. Most patients had a clinical stage T1
(71.8%), a biopsy Gleason score of 6 (88.8%), one
tumour-positive biopsy core (60.3%) and no comorbidity
(25%; Table 1). Table S4 shows patient characteristics at
time of PCa diagnosis for all patients included in the
GAP3 cohort for each participating centre. Patients on AS
had a median (IQR) follow-up time (i.e. the time until
discontinuation or the time until the last known follow-up
without discontinuation being reported) of 2.16 (1.02–
4.47) years. The maximum follow-up time was 21.3 years.
The median (IQR) number of years until patients’ last
follow-up while on AS was 1.99 (0.83–4.24) years
(Table 2).
By the end of current follow-up, 45 patients (0.3%) had
developed metastases and 566 patients (3.7%) had died, of
whom 37 (0.2%) died from PCa (Table 2). The main clinical
and demographic characteristics and clinical follow-up data
for all patients who developed metastases during AS (n = 45)
and for all patients who developed metastases and died from
PCa (n = 17) are summarized in Table 3. Of the patients who
had died from PCa by the end of current follow-up (n = 37),
a total of 32 patients had switched to curative treatment, of
whom 21 switched to androgen deprivation therapy, four to
external beam radiotherapy, two to external beam
radiotherapy and brachytherapy, one to external beam
radiotherapy and androgen deprivation, and four to radical
prostatectomy.
Table 1 Characteristics at time of prostate cancer diagnosis for all men
included in the GAP3 cohort*.
Characteristics Distribution of
characteristics
(N = 15 101)
Number of
centres
reported
(Ntotal = 25)
Median (IQR) age, years 65 (60–70) 25
Age, n (%)
≤55 years 1 547 (10.3) 25
56–60 years 2 402 (16.1)
61–65 years 3 579 (23.9)
66–70 years 4 002 (26.8)
71–80 years 3 256 (21.8)
>80 years 172 (1.1)
Year of diagnosis, n (%)
1992–1997 260 (1.8) 25
1998–2004 1 743 (11.6)
2005–2008 3 011 (20.2)
2009–2011 4 101 (27.5)
2012–2014 4 228 (28.4)
2015–2016 1 565 (10.5)
Charlson comorbidity index, n (%)
0 3 775 (25.0) 10
1 669 (4.4)
2 761 (5.0)
≥3 563 (3.7)
Missing 9 333 (61.8)
T stage (at DRE), n (%)
T1 10 841 (71.8) 23
T2 2 034 (13.5)
T3 11 (0.1)
T4 1 (<0.1)
Unknown 2 214 (14.6)
Gleason grade group, n (%)
<6 400 (2.7) 25
6 13 198 (88.8)
>6 1 263 (8.5)
Unknown 240 (1.6)
PSA level, n (%)
0–3.0 ng/mL 1 826 (12.6) 25
3.1–6.0 ng/mL 6 913 (47.8)
6.1–10.0 ng/mL 4 511 (31.2)
>10.0 ng/mL 1 207 (8.3)
Median (IQR) PSA, ng/mL 5.4 (4.0–7.3)
Missing PSA data, n (%) 644 (4.3)
Prostate volume
Median (IQR), cc 43.2 (33.0–59.0) 22
Missing, n (%) 4 069 (26.9)
PSA density
Median (IQR),
ng/mL
0.12 (0.09–0.17) 22
Missing, n (%) 4 221 (28.0)
Positive cores
Median (IQR) 1 (1–2) 24
Missing, n (%) 1 305 (8.6)
Positive cores
0 78 (0.6) 24
1 8 321 (60.3)
2 3 270 (23.7)
≥3 2 127 (15.4)
Percentage of cancer in any one core
Median (IQR) 10 (5–20) 17
Minimum, maximum, % 0, 100
Missing, n (%) 6 114 (40.5)
IQR, interquartile range. *Database version ‘gap3data_2.3’, released in June 2017.
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A total of 5 625 patients (37%) discontinued AS for the
following reasons: 46.2% for protocol-based progression; 3.3%
switched to watchful waiting; 9.1% discontinued through
patient or clinician choice; 7.0% died; and 25.1% discontinued
for unknown reasons. For all patients who discontinued AS,
treatment was reported in 73% of the cases (n = 4 124).
Treatment after discontinuation was radical prostatectomy in
51.6% of patients, external beam radiotherapy in 13.2% of
patients, brachytherapy in 9.3% of patients and primary
androgen deprivation/hormonal therapy in 8.4% of patients
(Table 2). Figure 1 shows the cumulative incidence curves of
reasons for discontinuing AS. The percentage of total area
shaded for each colour in the ﬁgure can be interpreted, at any
time point, as the risk of discontinuing AS for that stated
reason.
Of the 15 101 patients, 1 068 patients (7.1%) did not yet have
available follow-up data. Among the remaining 14 033
patients, after 5, 10 and 15 years of follow-up, respectively,
58%, 39% and 23% of patients were still on AS, 23%, 30%
and 36% discontinued because of protocol-based progression,
5%, 5% and 6% discontinued through patient or clinician
choice, 1%, 3% and 3% switched to watchful waiting, 2%, 7%
and 12% died (mostly from another cause), and 11%, 16%
and 20% discontinued for unknown reasons.
Discussion
In recent years, AS has evolved from an experimental
protocol to become a broadly accepted, in fact, preferred,
management strategy for men diagnosed with low-risk PCa
[15]. Nevertheless, consensus on inclusion criteria,
surveillance schedules and intervention thresholds for AS of
men with low-risk PCa is currently lacking. With this in
mind, the Movember Foundation launched the GAP3
initiative.
Several ﬁndings deserve particular attention. GAP3 is the
largest effort of its type to integrate patient data from men
with PCa on AS. With >15 000 patients, the Movember AS
database is the largest centralized PCa AS database to date,
Table 3 Clinical and demographic characteristics and clinical follow-up
for all patients who developed metastases during active surveillance and
for all patients who developed metastases and died from prostate
cancer*.
Characteristics Distribution of
characteristics
of patients who
developed
metastases
(N = 45)
Distribution of
characteristics of
patients who
developed
metastases
and died from
PCa (N = 17)
Median (IQR) age, years 66 (62–72) 66 (64–72)
Charlson comorbidity index, n (%)
0 45 (100) 17 (100)
1 0 (0) 0 (0)
2 0 (0) 0 (0)
≥3 0 (0) 0 (0)
Missing 0 (0) 0 (0)
T stage (at DRE), n (%)
T1 21 (46.7) 6 (35.3)
T2 15 (33.3) 7 (41.2)
T3 2 (4.4) 1 (5.9)
T4 1 (2.2) 1 (5.9)
Unknown 6 (13.3) 2 (11.8)
Gleason grade group, n (%)
<6 3 (6.7) 0 (0)
6 28 (62.2) 10 (58.8)
>6 21 (46.7) 5 (29.4)
Unknown 4 (8.9) 2 (11.8)
PSA ng/mL, n (%)
Median (IQR) 6.9 (4.8–8.7) 7.9 (4.3–12.5)
Missing, n (%) 4 (8.9) 1 (5.9)
Prostate volume, cc
Median (IQR) 44 (31–55) 41 (29–50)
Missing, n (%) 23 (51.1) 9 (52.9)
PSA density ng/mL/mL
Median (IQR) 0.14 (0.10–0.19) 0.14 (0.11–0.19)
Missing, n (%) 25 (55.6) 10 (58.8)
Positive cores, n (%)
0 – –
1 14 (42.4) 5 (29.4)
2 10 (30.3) 4 (23.5)
≥3 9 (27.3) 3 (17.6)
Median (IQR) time to
metastasis, years
6.4 (3.5–9.9) –
Median (IQR) time
to death, years
– 10.0 (6.1–12.7)
IQR, interquartile range; PCa, prostate cancer. *Database version ‘gap3data_2.3’,
released in June 2017.
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Fig. 1 Discontinuation of active surveillance (AS) over time (n = 14 033).
Protocol-based progression indicates clinical and pathological
progression, clinical progression, other PSA kinetics, pathological
progression, PSA progression (PSA doubling time <3 years), or
radiological progression.
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comprising the majority of the world’s AS patient data. Large
volumes of AS data have been collected routinely for many
years by the afﬁliated centres worldwide; hence, the central
data source enables comparisons of determinants for
inclusion and follow-up in AS, and subsequent clinical
outcomes (e.g. disease progression), between cohorts and
countries and it allows us to determine variable patterns over
time. Data capture is nearly complete (i.e. available for at
least 90% of the centres) for key variables such as: serum PSA
levels, Gleason score and clinical stage at time of PCa
diagnosis; serum PSA levels, T stage by DRE and biopsy
characteristics during follow-up; and reasons for
discontinuing AS, treatment choices and cause of death. The
database thus has a signiﬁcant amount of highly informative
patient data on AS for low-risk PCa. It can therefore make
signiﬁcant contributions to the development of evidence-
based consensus guidelines for AS, and as a result, improve
the lives of men diagnosed with low-risk PCa.
There are some limitations that need to be considered when
using data from GAP3. The database is ‘ambidirectional’,
meaning that it has both a retrospective and a prospective
component. Up until now, the GAP3 database has been
purely a retrospective database. As a consequence, there was
limited control over data collection, and the data of interest
were sometimes incomplete or inconsistently measured. For
instance, in 18 cohorts the reason for discontinuation of AS is
not available. For future analyses, the individual centres will
be requested to supply the missing data (if available). During
the course of the GAP3 project, it has become apparent that
there is an urgent need to assess the value of MRI with
respect to disease monitoring in patients on AS. The current
patient series has only limited imaging data from MRI, and
currently, almost no data are available for quality of life and
genomic testing. However, additional funding has now been
secured from the Movember Foundation to sustain the
database and to add a prospective element, thereby providing
the opportunity to collect evidence on imaging (MRI),
molecular (genomics) markers, patient-related outcomes and
more.
Metastatic disease or death from PCa are ultimate endpoints
by which AS should be evaluated [16]; however, because of
the slow-growing nature of low-risk PCa, prospective
evaluation of these endpoints requires at least another
10–15 years of follow-up [16]. To date, mainly data from
non-mature prospective clinical trials of AS, which have a
mean follow-up of <10 years, are available. The GAP3
database currently also has limited follow-up time, but will in
future provide the main resource of real-world data on AS
management.
In the global database, PCa death and metastasis remain rare
events (both <1%). Current analyses therefore make use of
surrogate endpoints such as discontinuation of AS and/or
changes in PCa treatment. Nevertheless, follow-up is ongoing
until at least 2019, so that in the future GAP3 will contain
even more valuable data and provide better insight into
patient outcomes.
Active surveillance is evolving into a well-accepted
management strategy for appropriately selected men. Unless
the over-diagnosis of indolent PCa is reduced by alternative
diagnostic strategies, AS will continue to play an important
role. The GAP3 initiative will make signiﬁcant contributions
to this ﬁeld of research by offering standard, evidence-based
guidelines [3]. Clinicians will be able to use these guidelines
more conﬁdently to identify patients who are suitable for AS
and also to decide whose PCa has progressed and will,
therefore, require treatment. Such guidelines will provide
reassurance to patients that they have made the best
treatment choice for their type of disease [3]. Longer follow-
up, achieved by ongoing commitment of GAP3 participating
centres, and the evaluation of, for instance, imaging and new
biomarkers, will result in more valuable data and eventually
in better patient outcomes.
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